Package 68727-745-02

{"route": ["INTRAVENOUS"], "spl_id": "25abb1d8-f921-4aae-8240-1914cd80417a", "openfda": {"nui": ["N0000000233", "N0000175595", "N0000175414", "M0028312", "N0000000176"], "unii": ["04079A1RDZ", "ZS7284E0ZP"], "rxcui": ["1942743", "1942748"], "spl_set_id": ["7ea701ce-e7d3-4349-a9c2-642a501d45c8"], "pharm_class_cs": ["Anthracyclines [CS]"], "pharm_class_epc": ["Nucleoside Metabolic Inhibitor [EPC]", "Anthracycline Topoisomerase Inhibitor [EPC]"], "pharm_class_moa": ["Nucleic Acid Synthesis Inhibitors [MoA]", "Topoisomerase Inhibitors [MoA]"], "manufacturer_name": ["Jazz Pharmaceuticals, Inc."], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "20 mL in 1 VIAL (68727-745-01)", "package_ndc": "68727-745-01", "marketing_start_date": "20170803"}, {"sample": false, "description": "40 mL in 1 CARTON (68727-745-02)", "package_ndc": "68727-745-02", "marketing_start_date": "20170803"}], "brand_name": "VYXEOS", "product_id": "68727-745_25abb1d8-f921-4aae-8240-1914cd80417a", "dosage_form": "INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION", "pharm_class": ["Anthracycline Topoisomerase Inhibitor [EPC]", "Anthracyclines [CS]", "Nucleic Acid Synthesis Inhibitors [MoA]", "Nucleoside Metabolic Inhibitor [EPC]", "Topoisomerase Inhibitors [MoA]"], "product_ndc": "68727-745", "generic_name": "(daunorubicin and cytarabine) liposome", "labeler_name": "Jazz Pharmaceuticals, Inc.", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "VYXEOS", "active_ingredients": [{"name": "CYTARABINE", "strength": "100 mg/20mL"}, {"name": "DAUNORUBICIN", "strength": "44 mg/20mL"}], "application_number": "NDA209401", "marketing_category": "NDA", "marketing_start_date": "20170803", "listing_expiration_date": "20271231"}